{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:17:02Z","timestamp":1788333422476,"version":"build-2803163510"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Nafamostat is a broad-spectrum serine protease inhibitor approved for pancreatitis, disseminated intravascular coagulation, and extracorporeal circulation anticoagulation. It also showed potential anti-SARS-CoV-2 activity during the COVID-19 pandemic, leading to expanded clinical use. This study aimed to explore post-marketing adverse event (AE) signals of nafamostat based on the Japanese Adverse Drug Event Report database so as to provide evidence for clinical safety management. Retrospective analysis was performed on AE reports retrieved from the Japanese Adverse Drug Event Report database between\n                      <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                      1 2004 and\n                      <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                      3 2024. Four disproportionality analysis algorithms, including reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker, were adopted to detect AE signals. The distribution of AEs across system organ classes and preferred terms was summarized, and the time to onset was analyzed using the Weibull shape parameter test. A total of 2051 valid AE reports with nafamostat as the primary suspected drug were included, covering 20 system organ classes. The most prominent signals were observed in immune system disorders (n\u2005=\u2005997) and vascular disorders (n\u2005=\u2005370). Twenty-four preferred terms met the screening criteria of all 4 algorithms, among which anaphylactic shock (n\u2005=\u2005746), shock (n\u2005=\u2005341), and hyperkalemia (n\u2005=\u2005200) were the most frequently reported. Six potential novel signals not recorded in the drug label were identified, namely acquired factor V deficiency, increased viral load, burning sensation, retroperitoneal hemorrhage, abdominal wall hematoma, and device-related thrombosis. Further bias analysis confirmed that 3 signals were false-positive results caused by confounding by indication or protopathic bias, while burning sensation had clear biological plausibility. The median time to onset was 1 day (interquartile range: 1\u20139 days); 58.55% of AEs occurred on the 1st day of administration, and 82.63% developed within 30 days. The Weibull test indicated that the AE risk peaked at the initial medication stage and gradually decreased over time. This real-world study clarified the safety profile of nafamostat, identifying severe allergic reactions and hyperkalemia as the main AEs. Of 6 initially detected unlabeled signals, 3 were confirmed as false-positive due to confounding bias, while the remaining 3 (bleeding complications and abnormal burning sensation) warrant clinical monitoring. Close monitoring within 24 hours after administration is highly recommended to reduce drug-related risks.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049803","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:02:56Z","timestamp":1784322176000},"page":"e49803","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety analysis of nafamostat: A retrospective pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database"],"prefix":"10.1097","volume":"105","author":[{"given":"Yi","family":"Yin","sequence":"first","affiliation":[{"name":"The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, P.R China"},{"name":"Department of Pediatric Intensive Care Unit, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, P.R China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0100-9714","authenticated-orcid":false,"given":"Guiju","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, P.R China"},{"name":"Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, P.R China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0005-2744(81)90023-1","article-title":"New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin.","volume":"661","author":"Fujii","year":"1981","journal-title":"Biochim Biophys Acta"},{"key":"R2-20260902","first-page":"685","article-title":"New synthetic inhibitor to the alternative complement pathway.","volume":"49","author":"Ikari","year":"1983","journal-title":"Immunology"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1254\/jjp.41.155","article-title":"Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats.","volume":"41","author":"Iwaki","year":"1986","journal-title":"Jpn J Pharmacol"},{"key":"R4-20260902","first-page":"374","article-title":"Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats.","volume":"13","author":"Yoshikawa","year":"1983","journal-title":"Haemostasis"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.eclinm.2021.101169","article-title":"Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised phase II clinical trial.","volume":"41","author":"Zhuravel","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"103856","DOI":"10.1016\/j.ebiom.2022.103856","article-title":"Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: phase 1b\/2a experimental study to investigate safety, pharmacokinetics and pharmacodynamics.","volume":"76","author":"Quinn","year":"2022","journal-title":"EBioMedicine"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijid.2022.12.039","article-title":"Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.","volume":"128","author":"Ikeda","year":"2023","journal-title":"Int J Infect Dis"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"106922","DOI":"10.1016\/j.ijantimicag.2023.106922","article-title":"Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: an exploratory multicentre randomized controlled clinical trial.","volume":"62","author":"Okugawa","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"e0097021","DOI":"10.1128\/mBio.00970-21","article-title":"The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19.","volume":"12","author":"Li","year":"2021","journal-title":"mBio"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19.","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/v12060629","article-title":"The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner.","volume":"12","author":"Yamamoto","year":"2020","journal-title":"Viruses"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJM199503093321018","article-title":"Hyperkalemia due to nafamostat mesylate.","volume":"332","author":"Kitagawa","year":"1995","journal-title":"N Engl J Med"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5301\/ijao.5000451","article-title":"Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.","volume":"38","author":"Park","year":"2015","journal-title":"Int J Artif Organs"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.12998\/wjcc.v8.i21.5320","article-title":"Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: four case reports.","volume":"8","author":"Okajima","year":"2020","journal-title":"World J Clin Cases"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/pcn.13785","article-title":"Second-generation antipsychotic-induced dystonia: analysis using the Japanese Adverse Drug Event Report (JADER) database.","volume":"79","author":"Ebina","year":"2025","journal-title":"Psychiatry Clin Neurosci"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/pcn.12793","article-title":"Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database.","volume":"73","author":"Anzai","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER).","volume":"29","author":"Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","article-title":"Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS.","volume":"42","author":"Ando","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction.","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"177933","DOI":"10.1016\/j.ejphar.2025.177933","article-title":"Post-marketing safety analysis of blonanserin: a retrospective pharmacovigilance study using the Japanese adverse drug event report database (2008\u20132024).","volume":"1003","author":"He","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"R21-20260902","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.","volume":"12","author":"Yin","year":"2022","journal-title":"Sci Rep"},{"key":"R22-20260902","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.gie.2008.10.046","article-title":"Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.","volume":"69","author":"Choi","year":"2009","journal-title":"Gastrointest Endosc"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MPA.0000000000000278","article-title":"Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.","volume":"44","author":"Ohuchida","year":"2015","journal-title":"Pancreas"},{"key":"R24-20260902","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00535-019-01644-z","article-title":"Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.","volume":"55","author":"Hirota","year":"2020","journal-title":"J Gastroenterol"},{"key":"R25-20260902","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/MPA.0000000000000625","article-title":"A randomized comparative study of 24- and 6-hour infusion of nafamostat mesilate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective randomized comparison trial.","volume":"45","author":"Kim","year":"2016","journal-title":"Pancreas"},{"key":"R26-20260902","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1007\/s10620-020-06782-6","article-title":"Nafamostat mesylate is not effective in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.","volume":"66","author":"Matsumoto","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R27-20260902","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/nep.14134","article-title":"Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006\u20132020.","volume":"28","author":"Wakasugi","year":"2023","journal-title":"Nephrology (Carlton)"},{"key":"R28-20260902","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(22)01441-6","article-title":"Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.","volume":"400","author":"Walli-Attaei","year":"2022","journal-title":"Lancet"},{"key":"R29-20260902","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5582\/bst.2024.01150","article-title":"The latest policies, practices, and hotspots in research in conjunction with the aging of Japan\u2019s population.","volume":"18","author":"Liu","year":"2024","journal-title":"Biosci Trends"},{"key":"R30-20260902","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/nep.13595","article-title":"Secular trends in end-stage kidney disease requiring renal replacement therapy in Japan: Japanese Society of Dialysis Therapy registry data from 1983 to 2016.","volume":"25","author":"Wakasugi","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"R31-20260902","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/1744-9987.12266","article-title":"Anticipated increase in the number of patients who require dialysis treatment among the aging population of Japan.","volume":"19","author":"Wakasugi","year":"2015","journal-title":"Ther Apher Dial"},{"key":"R32-20260902","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pds.1633","article-title":"Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.","volume":"17","author":"McAdams","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R33-20260902","first-page":"1148156","article-title":"Anaphylactic reactions caused by nafamostat mesylate during hemodialysis before surgery for carpal tunnel syndrome.","volume":"2021","author":"Nakamura","year":"2021","journal-title":"Case Rep Nephrol"},{"key":"R34-20260902","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000045822","article-title":"Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient.","volume":"86","author":"Higuchi","year":"2000","journal-title":"Nephron"},{"key":"R35-20260902","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nefroe.2019.02.005","article-title":"Sustained severe intestinal edema after nafamostat mesilate-associated anaphylactic reaction during hemodialysis.","volume":"39","author":"Shindo","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"key":"R36-20260902","first-page":"97","article-title":"Marked eosinophilia induced by nafamostat mesilate, an anticoagulant in a hemodialysis patient.","volume":"62","author":"Nakanishi","year":"1992","journal-title":"Nephron"},{"key":"R37-20260902","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/jpet.122.001248","article-title":"Nafamostat is a potent human diamine oxidase inhibitor possibly augmenting hypersensitivity reactions during nafamostat administration.","volume":"382","author":"Boehm","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"R39-20260902","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/medicina61020309","article-title":"Anticoagulation with nafamostat mesilate during impella support: a case report.","volume":"61","author":"Nakamura","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"R40-20260902","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00467-022-05567-5","article-title":"Anticoagulation strategies in continuous kidney replacement therapy \u2013 does one size fit all?","volume":"37","author":"Deep","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"R41-20260902","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-025-01604-y","article-title":"Charting and sidestepping the pitfalls of disproportionality analysis.","volume":"49","author":"Fusaroli","year":"2026","journal-title":"Drug Saf"},{"key":"R42-20260902","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001721-199909000-00004","article-title":"Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease?","volume":"10","author":"Kizaki","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R43-20260902","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0002-9149(93)90163-7","article-title":"Beneficial effects of a serine protease inhibitor in peripheral vascular disease.","volume":"72","author":"Urabe","year":"1993","journal-title":"Am J Cardiol"},{"key":"R44-20260902","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1111\/bph.14396","article-title":"Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome.","volume":"175","author":"Ceuleers","year":"2018","journal-title":"Br J Pharmacol"},{"key":"R45-20260902","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pain.2010.02.010","article-title":"Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway.","volume":"149","author":"Lam","year":"2010","journal-title":"Pain"},{"key":"R46-20260902","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/1756-0500-7-659","article-title":"Spontaneous retroperitoneal bleeding: a case series.","volume":"7","author":"Yamamura","year":"2014","journal-title":"BMC Res Notes"},{"key":"R47-20260902","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/01443610802237288","article-title":"Spontaneous iliopsoas haematoma during heparin anticoagulation: cause of fetal loss.","volume":"28","author":"Kurdoglu","year":"2008","journal-title":"J Obstet Gynaecol"},{"key":"R48-20260902","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin.","volume":"102","author":"Lim","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"R49-20260902","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/aor.14276","article-title":"Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: a systematic review.","volume":"46","author":"Sanfilippo","year":"2022","journal-title":"Artif Organs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:01:21Z","timestamp":1788332481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":48,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049803","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2026-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}